Commercialization of Human Genetic Research

Timothy Caulfield, University of Alberta, Edmonton, Canada

Published online: September 2006

DOI: 10.1002/9780470015902.a0005651

The commercialization of human genetic research is necessary to ensure that the public will benefit from the rapid advances occurring in this area. Despite the benefits of industry involvement in the commercialization process, numerous ethical, legal and social issues have emerged to the fore.

Keywords: genetics; biotechnology; commercialization; intellectual property; research

 References
    Andrews LB (1997) Past as prologue: sobering thoughts on genetic enthusiasm. Seton Hall Law Review 27: 893–918.
    Angell M (2000) Is academic medicine for sale? New England Journal of Medicine 342: 1516.
    Blumenthal D, Campbell EG, Andersen MS, et al. (1997) Withholding research results in academic life science: evidence from a national survey of faculty. Journal of the American Medical Association 277: 1224–1227.
    Cockburn I and Henderdon R (1996) Public–private interest in pharmaceutical research. Proceedings of the National Academy of Sciences The United States of America 93: 12725–12730.
    other European Community Working Group for the ELSI Aspects of Human Genome Analysis 1991. Report of 31 December 1991.
    Gold R (2000) Finding common cause in the patent debate. Nature Biotechnology 18: 1217–1218.
    Heller M and Eisenberg R (1998) Can patents deter innovation? The anticommons in biomedical research. Science 280: 698–701.
    Holtzman NA (1998) Bringing genetic tests into the clinic. Hospital Practice 33: 107–112.
    Holtzman NA (1999) Promoting safe and effective genetic tests in the United States: Work of the task force on genetic testing. Clinical Chemistry 45: 732–738.
    Knoppers B, Hirtle M and Glass K (1999) Commercialization of genetic research and public policy. Science 286: 227–228.
    Kodish E (1997) Commentary: risks and benefits, testing and screening, cancer, genes and dollars. Journal of Law, Medicine and Ethics 25: 252–255.
    Koenig BA, Greely HT, McConnell LM, Silverberg HL and Raffin TA (1998) Breast cancer working group of the Stanford program in genomics, ethics and society: genetic testing for BRCA1 and BRCA2: recommendations of the Stanford program in genomics, ethics and society. Journal of Women's Health 7: 531–545.
    book Lippman A (1998) "The politics of health: geneticization versus health promotion". In: Sherwin S et al. (eds.) The Politics of Women's Health. Philadelphia, PA: Temple University Press.
    book Nelkin D and Lindee MS (1995) The DNA Mystique: The Gene as a Cultural Icon. New York, NY: WH Freeman.
    Nelkin D and Andrews L (1998) Homo Economicus: commercialization of body tissue in the age of biotechnology. Hastings Center Report 28: 30–39.
    book Rifkin J (1998) The Biotech Century. New York, NY: Penguin Putman.
    book Secretary's Advisory Committee on Genetic Testing (SACGT) (2000) Enhancing the Oversight of Genetic Tests: Recommendations of the SACGT. National Institutes of Health, June 2000: http://www4.od.nih.gov/oba/sacgt.htm
    Testart J (1995) The new eugenics and medicalized reproduction. Cambridge Quarterly of Healthcare Ethics 4: 304–312.
    book Thomas S (1999) "Intellectual property rights and the human genome". In: Caulfield T and Williams-Jones B (eds.) The Commercialization of Genetic Research: Ethical, Legal and Policy Issues, pp. 55–62. New York: Kluwer Academic/Plenum Publishing.
    other UNESCO, Universal Declaration on the Human Genome and Human Rights, 11 November 1997. Available online at: www.unesco.org/human_rights/hrbc.htm.
    Varma R (1999) Professional autonomy vs industrial control? Science as Culture 8: 23–45.
    Welch HG and Burke W (1998) Uncertainties in genetic testing for chronic disease. JAMA 280: 1525–1527.
    book Weiss R (1999) Genetic testing's human toll. Washington Post 21 July: A1.
    book Weiss R and Nelson D (1999) Teen dies undergoing experimental gene therapy. Washington Post 29 September: http://www.washingtonpost.com/wp-srv/WPlate/1999-09/29
    book Willing R (2000) Gene patents get tougher. USA Today 15 November: 14A.
 Further Reading
    Blumenthal D (1992) Academic–industry relationships in the life sciences. Journal of the American Medical Association 268: 3344–3349.
    Blumenthal D (1996) Ethics issues in academic–industry relationships in the life sciences: the continuing debate. Academic Medicine 71: 1287–1290.
    Caulfield T (1999) The commercialization of human genetics: a discussion of issues relevant to Canadian consumers. Journal of Consumer Policy 21: 483–526.
    Heagerty A (1997) Commentary: industry-sponsored research. Lancet 349: 644–647.
    Healy H (1997) BRCA genes – bookmaking, fortunetelling, and medical care. New England Journal of Medicine 1448–1449.
    Knoppers B (1999) Status, sale and patenting of human genetic material: an international survey. Nature Genetics 22: 23–26.
    Marcus A (1996) Owning a gene: patent pending. Nature Medicine 2: 728–729.
    book Morgan D (1996) "The troubled helix: legal aspects of the new genetics". In: Marteau T and Richards M (eds.) The Troubled Helix, pp. 187–210. Cambridge, UK: Cambridge University Press.
    Otchet A (1999) The dangers of laissez faire. The UNESCO Courier September: 27–28.
    Pottage A (1998) The inscription of life in law: gene, patents, and bio-politics. The Modern Law Review 61: 740–765.

Related Sub-Topics:

Techniques and Tools in Clinical Genetics | Science and Society - General | Bioethics
Contact Editor close
Submit a note to the editor about this article by filling in the form below.

* Required Field

Article Title: Commercialization of Human Genetic Research
 
How to Cite close
Caulfield, Timothy(Sep 2006) Commercialization of Human Genetic Research. In: eLS. John Wiley & Sons Ltd, Chichester. http://www.els.net [doi: 10.1002/9780470015902.a0005651]